



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket Nos. 71369.368 and PFI-016CIPDV)

In re Application of: Orlow et al.) Examiner: To Be Assigned
Serial No. 10/758,335)
Filing Date: January 15, 2004)
Group Art Unit: 1614

For: METHODS AND COMPOSITIONS THAT AFFECT MELANOGENESIS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below.

5/21/04
Date

Sarah Farris
Sarah Farris

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Dear Sir:

Prior to issuance of a first Office Action on the merits, please amend the above-referenced application as follows:

In the Specification:

On page 17, please delete the paragraph at lines 1-3 and replace it with the following paragraph:

Figure 18 is a graphic representation providing measurements of tyrosinase activity of extract from melan-a melanocytes incubated with U18666A. Control cells received no drug treatment, and test cells were treated with 300 µM PTU, 10 µM IBMX, or 2.5 µM U18666A.

On page 17, please delete the paragraph at lines 4-6.

On page 81, please delete the paragraph at lines 13-15 and replace it with the following paragraph:

Results of the Western blot analysis show that the total amount of tyrosinase in the cell after exposure to U18666A is not significantly less than the control, untreated cell.